(Q34641561)

English

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

0 references

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis (English)

1 reference

Europe PubMed Central

3 August 2017

0 references

0 references

bipolar disorder

1 reference

based on heuristic

inferred from title

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

systematic review

1 reference

based on heuristic

inferred from title

Christoph Correll

6

object named as

Christoph U Correll

1 reference

Europe PubMed Central

3 August 2017

author name string

Marc De Hert

1

1 reference

Europe PubMed Central

3 August 2017

Weiping Yu

2

1 reference

Europe PubMed Central

3 August 2017

Johan Detraux

3

1 reference

Europe PubMed Central

3 August 2017

Kim Sweers

4

1 reference

Europe PubMed Central

3 August 2017

Ruud van Winkel

5

1 reference

Europe PubMed Central

3 August 2017

publication date

1 September 2012

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

26

1 reference

Europe PubMed Central

3 August 2017

9

1 reference

Europe PubMed Central

3 August 2017

733-759

1 reference

Europe PubMed Central

3 August 2017

https://scigraph.springernature.com/pub.10.2165/11634500-000000000-00000

0 references

Past and present progress in the pharmacologic treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Antipsychotic drugs and obesity

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Weight effects associated with antipsychotics: a comprehensive database analysis

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Weight gain in antipsychotic-naive patients: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Scales to assess the quality of randomized controlled trials: a systematic review

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study.

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

The role of serotonin receptors in the action of atypical antipsychotic drugs

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Once-monthly paliperidone injection for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

1 reference

https://api.crossref.org/works/10.2165%2F11634500-000000000-00000

21 January 2018

Update on Newer Antipsychotic Drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/22900950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents

1 reference

https://pubmed.ncbi.nlm.nih.gov/22900950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22900950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22900950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systematic evaluation and comparison of statistical tests for publication bias

1 reference

https://pubmed.ncbi.nlm.nih.gov/22900950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review

1 reference

https://pubmed.ncbi.nlm.nih.gov/22900950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22900950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22900950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22900950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/22900950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11634500-000000000-00000

1 reference

Europe PubMed Central

3 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34641561&oldid=1557610511"